Interferon alpha-2b

Drug Profile

Interferon alpha-2b

Alternative Names: Intron A; SCH 30500; Viraferon; Virtron; YM 14090

Latest Information Update: 20 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biogen Idec
  • Developer Biogen; Merck & Co
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia; Follicular lymphoma; Hairy cell leukaemia; Hepatitis B; Hepatitis C; Human papillomavirus infections; Malignant melanoma; Multiple myeloma; Non-Hodgkin's lymphoma

Most Recent Events

  • 13 Jun 2018 Merk prematurely terminates a phase II/III trial in Melanoma (Adjuvant therapy, Late-stage disease, Metastatic disease) due to sub-optimal accrual (SC, IV) (NCT03552549)
  • 17 Apr 2016 Biomarkers information updated
  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top